Formononetin and mizoribine inhibit Porcine Reproductive and Respiratory Syndrome Virus replication in vitro

Area of Science:

• Veterinary Virology
• Pharmacology
• Infectious Diseases

Background:

• Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) poses significant economic challenges to the swine industry.
• Current therapeutic options for PRRSV are limited, necessitating the exploration of novel antiviral agents.

Purpose of the Study:

• To evaluate the in vitro antiviral efficacy of Formononetin (FMN) and Mizoribine (MZR) against PRRSV.
• To assess the cytotoxicity of FMN and MZR and their potential synergistic effects with Ribavirin.

Main Methods:

• In vitro antiviral assays were performed using various PRRSV strains.
• Cytotoxicity assessments were conducted at specific concentrations of FMN and MZR.
• Synergistic effects were investigated when FMN and MZR were combined with Ribavirin.

Main Results:

• Both FMN and MZR demonstrated inhibition of multiple PRRSV strains in vitro.
• Antiviral activity was most pronounced during the early stages of viral infection.
• FMN and MZR exhibited low cytotoxicity at effective concentrations and showed synergistic effects with Ribavirin.

Conclusions:

• FMN and MZR are effective antiviral agents against PRRSV, particularly in early infection stages.
• The low cytotoxicity and synergistic potential of FMN and MZR highlight their promise as novel therapeutic candidates.
• These findings support the further development of FMN and MZR for PRRSV management strategies.